Related Experiment Video
Updated: Dec 7, 2025
06:15
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
1.7K
A Case Report on Bortezomib-Induced Bilateral Chalazion
Mahati Paravathaneni1, Vihitha Thota1, Sana Mulla1
1Internal Medicine, Mercy Catholic Medical Center, Darby, USA.
Cureus
|October 1, 2020
Summary
Bortezomib therapy for multiple myeloma can cause eyelid chalazion, a clogged oil gland. Early intervention and potential drug discontinuation can help manage this ocular side effect.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Chalazion is a common eyelid condition caused by blocked meibomian glands.
- Bortezomib is a proteasome inhibitor used to treat multiple myeloma (MM).
- Emerging evidence suggests a potential link between bortezomib treatment and chalazion development.
Observation:
- An 87-year-old female with MM developed bilateral chalazion after starting bortezomib.
- The patient received ophthalmological evaluation and treatment with lubricants and antibiotic drops.
- Bortezomib was temporarily halted until the chalazion resolved.
Findings:
- Bortezomib therapy is associated with the development of eyelid chalazion.
- This adverse ocular event can manifest as bilateral lesions.
- Management involves symptomatic treatment and potential modification of bortezomib therapy.
Implications:
- Physicians treating MM patients with bortezomib should monitor for ocular side effects like chalazion.
- Early recognition and management of bortezomib-induced chalazion are crucial.
- Awareness of this potential complication can guide treatment decisions and prevent severe eyelid issues.
